Axonics, Inc. AXNX shares are trading higher after the company reported preliminary fourth-quarter and full-year 2022 total net revenue results above estimates. The company also issued FY23 revenue guidance above estimates.
The company's quarterly net revenue is expected to be between $85.6 to $86.0 million, which is above the analyst consensus estimate of $74.3 million. For 2022, revenue is expected to be in the range of $273.6 million, which is above the analyst estimate of $262.38 million.
The company expects 2023 net revenue to be $342 million, versus the $327.2 million analyst estimate.
Axonics Inc, a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction.
AXNX Price Action: Axonics has a 52-week high of $79.915 and a 52-week low of $38.41.
Axonics shares are up 9.22% at $60.99 at time of publication, according to Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
